ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Novo powers rare disease startup Therachon to $60M round
fiercebiotech
August 10, 2018Therachon has?raised?$60 million (€52 million) to take a phase 1 rare disease drug deeper into the clinic. The Novo Holdings-led mezzanine round comes six months after Therachon began testing its FGFR3 ligand trap in healthy volunteers.
Pharma Sources Insight January 2025
